Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Nitrogen containing other than solely as a nitrogen in an...
Reexamination Certificate
2008-10-16
2010-10-26
Balasubramanian, Venkataraman (Department: 1624)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Nitrogen containing other than solely as a nitrogen in an...
C564S084000, C564S092000
Reexamination Certificate
active
07820717
ABSTRACT:
The invention relates to compounds represented by Structural Formula I, which can bind to CCR9 receptors and block the binding of a ligand (e.g., TECK) to the receptors. The invention also relates to a method of inhibiting a function of CCR9, and to the use compounds represented by Structural Formula I in research, therapeutic, prophylactic and diagnostic methods.
REFERENCES:
patent: 5217976 (1993-06-01), Ratcliffe et al.
patent: 5236937 (1993-08-01), Bradbury et al.
patent: 5294620 (1994-03-01), Ratcliffe et al.
patent: 5541186 (1996-07-01), Breu et al.
patent: 5589478 (1996-12-01), Yamada et al.
patent: 6136971 (2000-10-01), Harrington et al.
patent: 6939885 (2005-09-01), Ungashe et al.
patent: 7238717 (2007-07-01), Fleming et al.
patent: 7282502 (2007-10-01), Fleming et al.
patent: 2004/0167113 (2004-08-01), Ugashe et al.
patent: 2004/0171654 (2004-09-01), Ugashe et al.
patent: 2005/0137193 (2005-06-01), Ungashe et al.
patent: 2004/046092 (2004-06-01), None
patent: 2004/085384 (2004-10-01), None
patent: 2005/112925 (2005-12-01), None
Street, Jonathan D. et al., “Cyclising Nucleophilic Addition to Azinium Systems, Part 2. Reactions of 3-acylpyridinium hydrazones,”Journal of Chemical Research, Synopses, vol. 5 (1987), pp. 154-155 (abstract only).
Street, Jonathan D. et al., “Cyclising Nucleophilic Addition to Azinium Systems. Part 2. Reactions of 3-Acylpyridinium Hydrazones,”Journal of Chemical Research(S) (1987), pp. 154-155.
Danhardt, Gerd et al., “COX-1/COX-2 Inhibitors Based on the Methanone Moiety,”European Journal of Medicinal Chemistry, vol. 37, (Feb. 2002), pp. 147-161.
Supplementary European Search Report issued Feb. 1, 2006 in European Application No. EP 03755422.7, which corresponds to U.S. Appl. No. 10/443,155 and U.S. Appl. No. 12/288,075.
International Search Report issued on Oct. 20, 2003 in PCT Application No. PCT/US03/16090, which corresponds to U.S. Appl. No. 11/391,633 and U.S. Appl. No. 12/288,075.
Haste, Sigrid et al., “Chemokine Receptor Inhibition by AMD3100 is Strictly Confined to CXCR4,”FEBS Letters, vol. 527, (Sep. 11, 2002), pp. 255-262.
Street, Jonathan D. et al., “Cyclising Nucleophilic Addition to Azinium Systems,”Journal of Chemical Research Synopses, No. 5, (1987) pp. 154-155. CA 108:37599 (1988).
West, Anthony R., “Solid State Chemistry and Its Applications,” John Wiley & Sons, New York, (1988), pp. 358 & 365.
Vippagunta, S.R. et al., “Crystalline Solids,”Advanced Drug Delivery Reviews, vol. 48, No. 1, (May 2001), pp. 3-26.
Kelsall, Brian L. et al., “Involvement of Intestinal Dendritic Cells in Oral Tolerance, Immunity to Pathogens, and Inflammatory Bowel Disease,”Immunological Reviews, vol. 206, Issue 1, (Aug. 2005), pp. 132-148.
Yu, Cheng-Rong et al. “CCR9A and CCR9B: Two Receptors for the Chemokine CCL25/TECK/CkB-15 That Differ in Their Sensitivities to Ligand,”Journal of Immunology, vol. 164, (2000), pp. 1293-1305.
Hatoum, O.A. et al., “The Intestinal Microvasculature As a Therapeutic Target in Inflammatory Bowel Disease,”Annals of the New York Academy of Sciences., vol. 1072 ,(2006), pp. 78-97.
Silvestri et al. “Anti-HIV-1 NNRT Agents: Acylamino Pyrryl Aryl Sulfones (APASs) as Truncated Analogues of Tricyclic PBTDs,”Medicinal Chemistry Research, vol. 11, No. 4, (2002), pp. 195-218. CA 138: 187588 (2002).
Chen Shaowu
Fleming Paul
Harriman Geraldine C. B.
Shi Zhan
Balasubramanian Venkataraman
Millennium Pharmaceuticals Inc.
LandOfFree
CCR9 inhibitors and methods of use thereof does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with CCR9 inhibitors and methods of use thereof, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and CCR9 inhibitors and methods of use thereof will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-4240502